Login / Signup

Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy.

Simone KrebsJoseph A O'DonoghueEvan BiegelBradley J BeattieDiane ReidySerge K LyashchenkoJason S LewisLisa BodeiWolfgang A WeberNeeta Pandit-Taskar
Published in: European journal of nuclear medicine and molecular imaging (2020)
Our study shows that 68Ga-DOTA-JR11 PET can be used for patient selection and PRRT and that low tumor uptake on PET should not preclude patients from treatment with 177Lu-satoreotide tetraxetan. The ability to use single time-point SPECT/CT for absorbed dose calculations could facilitate dosimetry regimens, save costs, and improve patient convenience.
Keyphrases